Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.70 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.70 |
| ▸ | DRD2 | P14416 | 9/20 | 0.56 |
| ▸ | DRD3 | P35462 | 9/20 | 0.56 |
| ▸ | HTR2A | P28223 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838319 | 1.00 | KCNH2 (0.70) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4842018 | 1.00 | KCNH2 (0.70) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4838400 | 0.92 | KCNH2 (0.70) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4838380 | 0.92 | KCNH2 (0.70) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4837926 | 0.91 | KCNH2 (0.68) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4837284 | 0.91 | KCNH2 (0.68) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4839625 | 0.91 | KCNH2 (0.68) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4837296 | 0.91 | KCNH2 (0.68) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4839610 | 0.91 | KCNH2 (0.68) | KCNH2SCN9ASCN5ADRD2DRD3 | |
| SCHEMBL4837945 | 0.91 | KCNH2 (0.68) | KCNH2SCN9ASCN5ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157857-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2004-08-12 | — | — | US | claimed |
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | claimed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| EP-1025095-B1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 2003-11-26 | — | — | EP | claimed |
| US-20030100556-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2003-05-29 | — | — | US | claimed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | claimed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| EP-1021183-A1 | A COMBINATION OF A SELECTIVE 5-HT 1A? ANTAGONIST AND A SELECTIVE h5-HT 1B? ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-26 | — | — | EP | claimed |
| WO-1999013876-A1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | claimed |
| US-7384943-B2 | Substituted chroman derivatives | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20060223828-A1 | piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives; serotonin h5-HT1B receptor antagonist; regulate the synaptic concentration of serotonin by controlling the amount of 5-HT that is released; anxiolitic, antidepressant | BERG STEFAN | 2006-10-05 | — | — | US | disclosed |
| US-7056921-B2 | Substituted chroman derivatives | ASTRAZANECA AB (SE) | 2006-06-06 | — | — | US | disclosed |
| US-20040157857-A1 | Substituted chroman derivatives | BERG STEFAN (SE) | 2004-08-12 | — | — | US | disclosed |
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1021183-A1 | A COMBINATION OF A SELECTIVE 5-HT 1A? ANTAGONIST AND A SELECTIVE h5-HT 1B? ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-26 | — | — | EP | disclosed |
| EP-1014985-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT 1B ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999014212-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013876-A1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013877-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100556-A1 | Substituted chroman derivatives | NR2C2, NR0B1, NR0B2 | KCNH2 857/4885SCN9A 1092/4885SCN5A 905/4885 |
| US-20060223828-A1 | piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives; serotonin h5-HT1B receptor antagonist; regulate the synaptic concentration of serotonin by controlling the amount of 5-HT that is released; anxiolitic, antidepressant | HTR2B, HTR2C, HTR2A | KCNH2 529/4885SCN9A 829/4885SCN5A 466/4885 |
| US-20040157857-A1 | Substituted chroman derivatives | NR2C2, NR0B1, NR0B2 | KCNH2 857/4885SCN9A 1092/4885SCN5A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.